BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026

BridgeBio Pharma (BBIO) will present new data on oral infigratinib in achondroplasia at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026 in Marseille, France, on September 8–10, 2026.

Rhea-AI Summary

BridgeBio Pharma (BBIO) will present new data on oral infigratinib in achondroplasia at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026 in Marseille, France, on September 8–10, 2026.

The company highlights a late-breaking oral presentation from the randomized PROPEL 3 trial evaluating oral infigratinib’s impact on medical complications in children with achondroplasia, to be delivered by Julie Hoover-Fong, M.D., Ph.D., on September 9 at 10:00 am CEST. Two posters will cover longer-term efficacy and safety data and the PROPEL Infant & Toddler Phase 2/2b study in children under 3 years old, alongside an ePoster on medical challenges and functional impacts of hypochondroplasia. Oral infigratinib is described as an investigational FGFR3 inhibitor intended to improve bone growth in skeletal dysplasias such as achondroplasia and hypochondroplasia.

Market Context

BBIO's September 1 investor-conference announcement preceded a -0.03% 24-hour reaction. That record ...

Analysis

BBIO's September 1 investor-conference announcement preceded a -0.03% 24-hour reaction. That record places this presentation notice in a cautious recent-news backdrop; investors could watch the released clinical findings and any broader insider-selling signal.

Key Figures

Oral presentations: 1 late-breaking oral presentation Additional posters: 2 posters Additional eposters: 1 eposter +4 more

7 metrics

Oral presentations 1 late-breaking oral presentation Annual ESPE Meeting 2026

Additional posters 2 posters Annual ESPE Meeting 2026

Additional eposters 1 eposter Annual ESPE Meeting 2026

Trial phase Phase 2/2b PROPEL Infant and Toddler study

Study population age under 3 years old Children with achondroplasia

Achondroplasia population approximately 55,000 people United States and European Union

Children and adolescents up to 10,000 People with open growth plates in the U.S. and EU

Historical Context

5 past events · Latest: Sep 1 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 1	Investor conference	Neutral	-0.0%	Management announced participation in multiple September healthcare investor conferences with webcast availability.
Aug 31	Access agreement	Positive	-0.0%	Company announced a voluntary government agreement expanding Medicaid access and addressing medicine affordability.
Aug 26	Trial initiation	Positive	-1.3%	Company dosed the first participant in a long-term acoramidis ATTR-CM study.
Aug 24	Clinical presentation	Neutral	-0.5%	Company announced open-label extension and AI-enabled ATTR-CM analyses at ESC Congress.
Aug 14	Secondary offering	Negative	-1.7%	Existing shareholder KKR priced a secondary sale; BridgeBio would receive no proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent BridgeBio announcements were generally followed by negative price reactions, including several informational or operational updates.

Key Terms

randomized controlled trial, phase 2/2b, fgfr3, mapk, +2 more

6 terms

randomized controlled trial medical

"A Randomized Controlled Trial of Oral Infigratinib in Children with Achondroplasia"

A randomized controlled trial is a research method that tests the effects of a new idea or treatment by randomly dividing participants into two groups: one that receives the treatment and one that does not. This approach helps ensure that the results are fair and unbiased, providing clear evidence about whether the treatment actually works. Investors value such trials because they offer reliable information that can influence decision-making and reduce uncertainty.

phase 2/2b medical

"an ongoing Phase 2/2b study in children under 3 years old"

Phase 2/2b denotes mid-stage clinical studies that test whether a new drug or treatment works in patients and what dose is best. Phase 2 often explores safety and early signs of benefit in a smaller group, while a Phase 2b is a larger, more rigorous test focused on confirming the right dose and proof of effect before a costly, definitive Phase 3 trial. Investors watch these results because positive Phase 2/2b data meaningfully reduce scientific and commercial uncertainty and can materially change a company’s valuation; negative results raise risk and can sharply lower prospects.

fgfr3 medical

"The condition is uniformly caused by an activating variant in FGFR3."

FGFR3 is a gene that makes a protein sitting on the surface of cells which helps control growth and division, like a light switch that tells a cell when to grow. Changes in FGFR3 can drive certain cancers or other growth disorders, so tests and drugs that target it can be important for diagnosing disease, selecting patients for treatments, and creating new therapies — all of which affect the commercial prospects and risk profile of biotech investments.

mapk technical

"drive downstream MAPK and STAT1 signaling"

MAPK (Mitogen‑Activated Protein Kinase) is a family of enzymes in cells that act like switches or traffic signals, passing along messages that tell cells to grow, divide, or respond to stress. It matters to investors because abnormal MAPK signaling is implicated in cancers and other diseases, making these enzymes common targets for drugs and diagnostics; progress or setbacks in MAPK‑related research can materially affect the value of biotech and pharmaceutical companies.

stat1 technical

"drive downstream MAPK and STAT1 signaling"

STAT1 is a human gene and the protein it makes, a messenger that carries signals from immune-related molecules into the cell nucleus to turn other genes on or off; it acts like a light switch that helps control immune and antiviral responses. It matters to investors in healthcare and biotech because drugs, diagnostics, or trial results that target or measure STAT1 can indicate how therapies work, serve as biomarkers, or affect regulatory and commercial prospects.

skeletal dysplasias medical

"target skeletal dysplasias, including achondroplasia and hypochondroplasia"

A group of rare, usually genetic disorders that disrupt normal bone and cartilage growth, producing short stature, abnormal bone shape, joint problems, and sometimes other organ issues; think of them as inherited “blueprint” errors that affect how the skeleton is built. They matter to investors because they define a specific patient population, clinical trial design, regulatory pathways, and potential markets for drugs, medical devices, and diagnostics aimed at treating or managing these conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one late-breaking oral presentation on the impact of oral infigratinib on medical complications in achondroplasia from PROPEL 3 will be shared at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026, taking place in Marseille, France on September 8-10, 2026.

In addition to the late-breaking oral presentation, two posters and one eposter will be shared on longer-term data for oral infigratinib in achondroplasia, PROPEL I&T–an ongoing Phase 2/2b study in children under 3 years old with achondroplasia, and qualitative research on the impacts of hypochondroplasia.

BridgeBio is committed to exploring the potential of oral infigratinib on wider medical and functional impacts of achondroplasia, hypochondroplasia and other skeletal dysplasia conditions, which hold significant unmet needs for families.

Late-Breaking Oral Presentation:
A Randomized Controlled Trial of Oral Infigratinib in Children with Achondroplasia: Results from the PROPEL 3 Study
Presenter: Julie Hoover-Fong, M.D., Ph.D., Johns Hopkins University, U.S.
Date: Wednesday, September 9 at 10:00 am CEST

Posters:
Longer-Term Efficacy and Safety Results of Infigratinib in Children with Achondroplasia
Presenter: Melita Irving, M.D., Guy's and St Thomas' NHS Foundation Trust, London, UK

PROPEL Infant and Toddler: Study Design and Ongoing Enrollment of a Phase 2/2b Study of Infigratinib in Children under 3 Years Old with Achondroplasia
Presenter: Melita Irving, M.D., Guy's and St Thomas' NHS Foundation Trust, London, UK

ePoster:
Potential Medical Challenges and Functional Impacts of Hypochondroplasia: Qualitative Interviews with Children and Parents
Presenter: Melita Irving, M.D., Guy’s and St Thomas’ NHS Foundation Trust, London, UK

About Achondroplasia
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the U.S. and European Union (EU), including up to 10,000 children and adolescents with open growth plates. Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. The condition is uniformly caused by an activating variant in FGFR3.

About Oral Infigratinib
Oral infigratinib is an investigational small molecule designed to inhibit FGFR3 signaling and target skeletal dysplasias, including achondroplasia and hypochondroplasia, at their source. Overactivating FGFR3 pathogenic variants drive downstream MAPK and STAT1 signaling that aberrates growth plate development, thereby causing disproportionate short stature and the potential for serious health complications. Oral infigratinib improves bone growth by decreasing the overactivity of FGFR3.

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com   
(650) 789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com 

FAQ

What did BridgeBio Pharma (BBIO) announce regarding oral infigratinib and achondroplasia at ESPE 2026?

BridgeBio announced that new data on oral infigratinib in achondroplasia will be presented at the ESPE 2026 Meeting, including a late-breaking oral presentation from the randomized PROPEL 3 trial, two posters on longer-term data and the PROPEL Infant & Toddler study, and one ePoster on hypochondroplasia impacts.

When and where will BridgeBio (BBIO) present the PROPEL 3 achondroplasia data on oral infigratinib?

The late-breaking PROPEL 3 oral presentation is scheduled for Wednesday, September 9, 2026 at 10:00 am CEST during the Annual ESPE Meeting 2026, which takes place in Marseille, France from September 8–10, 2026.

What studies on oral infigratinib in achondroplasia will BridgeBio (BBIO) feature at ESPE 2026?

BridgeBio will feature a late-breaking oral presentation on the randomized PROPEL 3 trial, a poster on longer-term efficacy and safety in children with achondroplasia, and a poster on PROPEL Infant and Toddler, an ongoing Phase 2/2b study in children under 3 years old with achondroplasia.

What is oral infigratinib and how is it intended to work in achondroplasia and hypochondroplasia?

Oral infigratinib is an investigational small molecule FGFR3 inhibitor designed to target skeletal dysplasias such as achondroplasia and hypochondroplasia at their source. By decreasing overactive FGFR3 signaling, it is described as improving bone growth and addressing downstream pathways that affect growth plate development.

How common is achondroplasia and what complications does BridgeBio (BBIO) highlight?

Achondroplasia is described as the most common cause of disproportionate short stature, affecting about 55,000 people in the U.S. and EU, including up to 10,000 children and adolescents with open growth plates. Reported complications include obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis.

Which additional condition related to FGFR3 is included in BridgeBio’s (BBIO) ESPE 2026 presentations?

Beyond achondroplasia, BridgeBio will present an eposter on hypochondroplasia titled “Potential Medical Challenges and Functional Impacts of Hypochondroplasia,” based on qualitative interviews with children and parents, reflecting the company’s interest in broader skeletal dysplasia indications.